INDEMNIFICATION AGREEMENTIndemnification Agreement • April 1st, 2021 • Anebulo Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [insert date] between Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”).
INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • March 12th, 2021 • Anebulo Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 18th day of June, 2020, by and among Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
●] Shares1 Anebulo Pharmaceuticals, Inc. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENTUnderwriting Agreement • April 26th, 2021 • Anebulo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company. The Firm Shares consist of authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company also proposes to grant to the several Underwriters an option to purchase up to [●] additional shares of Common Stock on the terms and for the purposes set forth in Section 3(b) hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Securities.”
RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENTSale Agreement • March 12th, 2021 • Anebulo Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (this “Agreement”), is made as of the 18th day of June, 2020 by and among Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Investors (as defined below) listed on Schedule A and the Key Holders (as defined below) listed on Schedule B.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 29th, 2022 • Anebulo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”), dated as of September 25, 2022, is made by and among Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Purchasers listed on Exhibit A hereto, together with their permitted transferees (each, a “Purchaser” and collectively, the “Purchasers”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 6th, 2023 • Anebulo Pharmaceuticals, Inc. • Pharmaceutical preparations • Texas
This Employment Agreement (the “Agreement”), effective as of October 5, 2023 (the “Effective Date”), is made by and between Richard Anthony Cunningham (the “Executive”) and Anebulo Pharmaceuticals, Inc., a Delaware corporation (together with any of its subsidiaries and affiliates as may employ the Executive from time to time, and any successor(s) thereto, the “Company”).
ContractWarrant Purchase Agreement • April 1st, 2021 • Anebulo Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT.
CONSULTANCY AGREEMENTConsultancy Agreement • April 1st, 2021 • Anebulo Pharmaceuticals, Inc. • Pharmaceutical preparations • Texas
SERIES A PREFERRED STOCK PURCHASE AGREEMENTSeries a Preferred Stock Purchase Agreement • March 12th, 2021 • Anebulo Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS SERIES A PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of the 18th day of June, 2020 by and among Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the investors listed on Exhibit A attached to this Agreement (each a “Purchaser” and together the “Purchasers”).
LICENCE AGREEMENT DatedLicence Agreement • March 12th, 2021 • Anebulo Pharmaceuticals, Inc. • Pharmaceutical preparations • England and Wales
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • April 1st, 2021 • Anebulo Pharmaceuticals, Inc. • Pharmaceutical preparations • Texas
This Amendment No. 1 to the Employment Agreement (this “Amendment”) is made as of the 22nd day of January, 2021 (the “Effective Date”) by and between Daniel Schneeberger, whose address is 7816 Lynchburg Drive, Austin, TX 78738 (the “Employee”) and Anebulo Pharmaceuticals, Inc. (the “Company”).
MASTER SERVICES AGREEMENTMaster Services Agreement • March 8th, 2023 • Anebulo Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Master Services Agreement (the “Agreement”) is made effective as of March 2, 2023 (the “Effective Date”), by and between Anebulo Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business being 1415 Ranch Road 620 South, Suite 201, Lakeway, TX 78734 (the “Company”) and Potrero Hill Advisors, LLC., a California limited liability corporation, with its principal place of business being 2010 El Camino Real #1311, Santa Clara, CA 95050 (“Potrero”). The Company and Potrero are herein sometimes referred to individually as a “Party” and collectively as the “Parties.”
JFL Capital ManagementAnebulo Pharmaceuticals, Inc. • September 9th, 2022 • Pharmaceutical preparations
We are the tenant of the Leased Premises, leased by us from Prosperity Bank (“Lessor”), in accordance with the covenants, agreements, terms, provisions and conditions of leases (“Leases”) for the Leased Premises.
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • November 14th, 2023 • Anebulo Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of November 13, 2023 (the “Effective Date”) among (a) 22NW, LP (“22NW”), in its capacity as administrative agent and collateral agent (“Agent”), (b) 22NW, as a lender, (c) JFL Capital Management LLC (“JFL”) as a lender (22NW, in its capacity as a lender hereunder, JFL and each of the other “Lenders” from time to time party hereto are referred to herein collectively as the “Lenders” and each individually as a “Lender”), and (d) Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Borrower”). The parties agree as follows:
